• MeSH
• Allergens therapeutic use   MeSH
• Hypersensitivity prevention & control   MeSH
• Immunotherapy MeSH
• Publication type
• Congress MeSH
• Collected Work MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• alergologie a imunologie

• MeSH
• Evidence-Based Medicine methods   trends   MeSH
• Paranasal Sinus Diseases diagnosis   epidemiology   therapy   MeSH
• Nasal Polyps diagnosis   epidemiology   therapy   MeSH
• Publication type
• Collected Work MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• otorinolaryngologie
• alergologie a imunologie

• MeSH
• Immunotherapy, Active MeSH
• Allergens MeSH
• Hypersensitivity therapy   MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• alergologie a imunologie
• NML Publication type
• publikace WHO

BACKGROUND: Since publication of the original Position Paper on Olfactory Dysfunction in 2017 (PPOD-17), the personal and societal burden of olfactory disorders has come sharply into focus through the lens of the COVID-19 pandemic. Clinicians, scientists and the public are now more aware of the importance of olfaction, and the impact of its dysfunction on quality of life, nutrition, social relationships and mental health. Accordingly, new basic, translational and clinical research has resulted in significant progress since the PPOD-17. In this updated document, we present and discuss currently available evidence for the diagnosis and management of olfactory dysfunction. Major updates to the current version include, amongst others: new recommendations on olfactory related terminology; new imaging recommendations; new sections on qualitative OD and COVID-19 OD; updated management section. Recommendations were agreed by all co-authors using a modified Delphi process. CONCLUSIONS: We have provided an overview of current evidence and expert-agreed recommendations for the definition, investigation, and management of OD. As for our original Position Paper, we hope that this updated document will encourage clinicians and researchers to adopt a common language, and in so doing, increase the methodological quality, consistency, and generalisability of work in this field.

• MeSH
• Smell MeSH
• COVID-19 * MeSH
• Quality of Life MeSH
• Humans MeSH
• Pandemics MeSH
• Olfaction Disorders * diagnosis   therapy   epidemiology   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH

• MeSH
• Anaphylaxis * chemically induced   diagnosis   therapy   MeSH
• Anti-Bacterial Agents adverse effects   MeSH
• Anti-Inflammatory Agents, Non-Steroidal adverse effects   MeSH
• Diagnosis, Differential MeSH
• Child MeSH
• Skin Tests MeSH
• Drug Hypersensitivity diagnosis   pathology   therapy   MeSH
• Humans MeSH
• Drug-Related Side Effects and Adverse Reactions epidemiology   MeSH
• Risk Factors MeSH
• Check Tag
• Child MeSH
• Humans MeSH
• Publication type
• Review MeSH

• MeSH
• Endoscopy methods   trends   utilization   MeSH
• Skull Base Neoplasms diagnosis   etiology   therapy   MeSH
• Nose Neoplasms diagnosis   classification   therapy   MeSH
• Paranasal Sinus Neoplasms diagnosis   etiology   therapy   MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• otorinolaryngologie
• NML Publication type
• studie

• MeSH
• Arthritis, Rheumatoid drug therapy   MeSH
• Publication type
• News MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• revmatologie
• farmakoterapie

The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery. EPOS2020 also involves new stakeholders, including pharmacists and patients, and addresses new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements in research in different settings. EPOS2020 contains chapters on definitions and classification where we have defined a large number of terms and indicated preferred terms. A new classification of CRS into primary and secondary CRS and further division into localized and diffuse disease, based on anatomic distribution is proposed. There are extensive chapters on epidemiology and predisposing factors, inflammatory mechanisms, (differential) diagnosis of facial pain, allergic rhinitis, genetics, cystic fibrosis, aspirin exacerbated respiratory disease, immunodeficiencies, allergic fungal rhinosinusitis and the relationship between upper and lower airways. The chapters on paediatric acute and chronic rhinosinusitis are totally rewritten. All available evidence for the management of acute rhinosinusitis and chronic rhinosinusitis with or without nasal polyps in adults and children is systematically reviewed and integrated care pathways based on the evidence are proposed. Despite considerable increases in the amount of quality publications in recent years, a large number of practical clinical questions remain. It was agreed that the best way to address these was to conduct a Delphi exercise . The results have been integrated into the respective sections. Last but not least, advice for patients and pharmacists and a new list of research needs are included. The full document can be downloaded for free on the website of this journal: http://www.rhinologyjournal.com.

• MeSH
• Acute Disease MeSH
• Chronic Disease MeSH
• Child MeSH
• Adult MeSH
• Humans MeSH
• Nasal Polyps * diagnosis   therapy   MeSH
• Rhinitis * diagnosis   therapy   MeSH
• Sinusitis * diagnosis   therapy   MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Humans MeSH
• Publication type
• Journal Article MeSH
• Practice Guideline MeSH

Facially disfigured blind patients have historically been considered for face transplantation with skepticism. Although no formal position paper regarding their exclusion has been published to date, functional, social, rehabilitative, and ethical concerns related to blind patients' candidacy for face transplantation may be inferred. The authors provide a summary of these reservations and a counterargument to their assumptions, drawing on outcomes measures reported for face transplant procedures performed to date, and their own institutional experience in performing face transplants on blind patients. The authors therefore provide a rationale for the inclusion of facially disfigured blind patients in face transplantation protocols in the future.

• MeSH
• Interpersonal Relations MeSH
• Humans MeSH
• Facial Injuries complications   psychology   surgery   MeSH
• Eye Injuries complications   psychology   MeSH
• Self Concept MeSH
• Blindness etiology   psychology   MeSH
• Facial Transplantation * ethics   psychology   rehabilitation   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, U.S. Gov't, Non-P.H.S. MeSH

• MeSH
• HIV Infections prevention & control   therapy   MeSH
• Organizational Policy MeSH
• National Health Programs MeSH

• Conspectus
• Veřejné zdraví a hygiena
• NML Fields
• dermatovenerologie
• veřejné zdravotnictví